Search Results

There are 10001 results for: content related to: Tegaserod, a 5-HT 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

  1. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation

    Intervention Review

    The Cochrane Library

    Beti W Evans, Wendy K Clark, David J Moore and Peter J Whorwell

    Published Online : 17 OCT 2007, DOI: 10.1002/14651858.CD003960.pub3

  2. You have free access to this content
    Influence of tegaserod on proximal gastric tone and on the perception of gastric distension

    Alimentary Pharmacology & Therapeutics

    Volume 18, Issue 10, November 2003, Pages: 1031–1037, J. Tack, R. Vos, J. Janssens, J. Salter, S. Jauffret and G. Vandeplassche

    Version of Record online : 20 OCT 2003, DOI: 10.1046/j.1365-2036.2003.01775.x

  3. You have free access to this content
    Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats

    British Journal of Pharmacology

    Volume 158, Issue 5, November 2009, Pages: 1210–1226, Evelin Painsipp, Anaid Shahbazian and Peter Holzer

    Version of Record online : 28 SEP 2009, DOI: 10.1111/j.1476-5381.2009.00392.x

  4. You have free access to this content
    The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo

    British Journal of Pharmacology

    Volume 143, Issue 5, November 2004, Pages: 549–560, D T Beattie, J A M Smith, D Marquess, R G Vickery, S R Armstrong, T Pulido-Rios, J L McCullough, C Sandlund, C Richardson, N Mai and P P A Humphrey

    Version of Record online : 17 FEB 2009, DOI: 10.1038/sj.bjp.0705929

  5. Activation of peripheral 5-HT4 receptors attenuates colonic sensitivity to intraluminal distension

    Neurogastroenterology & Motility

    Volume 18, Issue 1, January 2006, Pages: 76–86, B. Greenwood-van Meerveld, K. Venkova, G. Hicks, E. Dennis and M. D. Crowell

    Version of Record online : 14 OCT 2005, DOI: 10.1111/j.1365-2982.2005.00723.x

  6. Influence of a new 5-HT4 receptor partial agonist, YKP10811, on visceral hypersensitivity in rats triggered by stress and inflammation

    Neurogastroenterology & Motility

    Volume 26, Issue 12, December 2014, Pages: 1761–1770, M. Gilet, H. Eutamene, H. Han, H. W. Kim and L. Bueno

    Version of Record online : 15 OCT 2014, DOI: 10.1111/nmo.12458

  7. You have free access to this content
    Tegaserod

    Alimentary Pharmacology & Therapeutics

    Volume 15, Issue 3, March 2001, Pages: 277–289, M. Camilleri

    Version of Record online : 7 JUL 2008, DOI: 10.1046/j.1365-2036.2001.00925.x

  8. Neurogastroenterology of tegaserod (HTF 919) in the submucosal division of the guinea-pig and human enteric nervous system

    Neurogastroenterology & Motility

    Volume 20, Issue 1, January 2008, Pages: 80–93, X. Fang, S. Liu, X-y. Wang, N. Gao, H-z. Hu, G-d. Wang, C. H. Cook, B. J. Needleman, D. J. Mikami, Y. Xia, G-j. Fei, G. A. Hicks and J. D. Wood

    Version of Record online : 28 AUG 2007, DOI: 10.1111/j.1365-2982.2007.00983.x

  9. You have free access to this content
    Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation

    Alimentary Pharmacology & Therapeutics

    Volume 21, Issue 1, January 2005, Pages: 11–20, S. Müller-Lissner, G. Holtmann, P. Rueegg, G. Weidinger and H. Löffler

    Version of Record online : 22 DEC 2004, DOI: 10.1111/j.1365-2036.2004.02294.x

  10. You have free access to this content
    The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease

    Alimentary Pharmacology & Therapeutics

    Volume 14, Issue 11, November 2000, Pages: 1503–1509, P. J. Kahrilas, E. M. M. Quigley, D. O. Castell and S. J. Spechler

    Version of Record online : 24 DEC 2001, DOI: 10.1046/j.1365-2036.2000.00854.x

  11. A systematic review of tegaserod for the treatment of irritable bowel syndrome

    Journal of Clinical Pharmacy and Therapeutics

    Volume 27, Issue 5, October 2002, Pages: 343–352, B. W. Jones, D. J. Moore, S. M. Robinson and F. Song

    Version of Record online : 15 OCT 2002, DOI: 10.1046/j.1365-2710.2002.00426.x

  12. You have free access to this content
    Review article: the safety profile of tegaserod

    Alimentary Pharmacology & Therapeutics

    Volume 20, Issue s7, November 2004, Pages: 25–30, P. Schoenfeld

    Version of Record online : 1 NOV 2004, DOI: 10.1111/j.1365-2036.2004.02182.x

  13. You have free access to this content
    The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects—male and female, elderly and young

    Alimentary Pharmacology & Therapeutics

    Volume 15, Issue 7, July 2001, Pages: 937–944, S. Appel-Dingemanse, A. Horowitz, J. Campestrini, S. Osborne and J. Mcleod

    Version of Record online : 12 JAN 2002, DOI: 10.1046/j.1365-2036.2001.00973.x

  14. You have free access to this content
    A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

    Alimentary Pharmacology & Therapeutics

    Volume 16, Issue 11, November 2002, Pages: 1877–1888, J. Novick, P. Miner, R. Krause, K. Glebas, H. Bliesath, G. Ligozio, P. Rüegg and M. Lefkowitz

    Version of Record online : 17 OCT 2002, DOI: 10.1046/j.1365-2036.2002.01372.x

  15. Tegaserod Pharmacokinetics Are Similar in Patients with Severe Renal Insufficiency and in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 43, Issue 4, April 2003, Pages: 359–364, Dr Suzanne K. Swan, Dr Honghui Zhou, Dr Ann Horowitz, Dr Latifa Alladina, Dr Martine Hubert, Dr Silke Appel-Dingemanse, Mr Stuart Osborne, Dr Larry Lambrecht and Dr James F. McLeod

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270003251823

  16. You have free access to this content
    Review article: tegaserod — the global experience

    Alimentary Pharmacology & Therapeutics

    Volume 20, Issue s7, November 2004, Pages: 15–19, W. D. Chey

    Version of Record online : 1 NOV 2004, DOI: 10.1111/j.1365-2036.2004.02181.x

  17. Influence of tegaserod on proximal gastric tone and on the perception of gastric distention in functional dyspepsia

    Neurogastroenterology & Motility

    Volume 23, Issue 2, February 2011, Pages: e32–e39, J. Tack, P. Janssen, R. Bisschops, R. Vos, T. Phillips and G. Tougas

    Version of Record online : 27 OCT 2010, DOI: 10.1111/j.1365-2982.2010.01613.x

  18. Safety, tolerability and satisfaction with tegaserod therapy in Asia–Pacific patients with irritable bowel syndrome with constipation

    Journal of Gastroenterology and Hepatology

    Volume 22, Issue 8, August 2007, Pages: 1190–1198, Kwong M Fock, Amy Wagner and the Asia Pacific Gastroenterology Group

    Version of Record online : 24 MAY 2007, DOI: 10.1111/j.1440-1746.2007.04955.x

  19. You have free access to this content
    Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects

    Alimentary Pharmacology & Therapeutics

    Volume 15, Issue 11, November 2001, Pages: 1745–1751, L. Degen, D. Matzinger, M. Merz, S. Appel-Dingemanse, S. Osborne, S. Lüchinger, R. Bertold, H. Maecke and C. Beglinger

    Version of Record online : 7 JUL 2008, DOI: 10.1046/j.1365-2036.2001.01103.x

  20. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial

    Neurogastroenterology & Motility

    Volume 19, Issue 10, October 2007, Pages: 821–830, A. E. Foxx-orenstein, M. Camilleri, L. A. Szarka, S. Mckinzie, D. Burton, G. Thomforde, K. Baxter and A. R. Zinsmeister

    Version of Record online : 21 MAY 2007, DOI: 10.1111/j.1365-2982.2007.00944.x